Hypermagnesemia linked to cardiovascular events, mortality in CKD
Click Here to Manage Email Alerts
Researchers from Spain found that for patients with chronic kidney disease, serum magnesium levels increased as kidney function declined and that individuals with hypermagnesemia had an elevated risk for cardiovascular events and mortality.
These findings led Isabel Galán, MD, of Hospital General Universitario Reina Sofia, and colleagues to recommend health care providers use caution when recommending magnesium supplementation to patients with CKD.
“In the general population, hypomagnesemia has been associated with cardiovascular events and hypermagnesemia with overall mortality,” the researchers wrote. “In chronic kidney disease (CKD), the evidence is not so strong. The objective of our study was to investigate the relationship between serum magnesium (SMg) concentration and cardiovascular morbidity and mortality, all-cause mortality and the progression to kidney failure in a population with CKD.”
For the study, Galán and colleagues considered the characteristics and analytical profiles of 746 patients, collecting these at a first nephrology visit (mean SMg concentration, 2.09 mg/dL). Cardiovascular events included acute myocardial infarction, congestive heart failure, ischemic or hemorrhagic cerebrovascular disease and other ischemic events.
After a mean follow-up of 42.6 months, 45.7% patients either reached a CV event, initiated kidney replacement therapy or died.
While no association was found between SMg concentration and initiation of kidney replacement therapy, researchers observed a “close correlation” between SMg concentration and serum creatinine, phosphorus and intact parathyroid hormone values.
“Magnesium values increase as CKD advances,” the researchers wrote. “SMg is associated with age, kidney function, serum phosphorus concentration and hyperparathyroidism, as well as treatment with calcitriol.”
Further, patients with hypermagnesemia had an increased adjusted risk for both cardiovascular events (HR = 1.34) and all-cause mortality (HR = 1.54).
“In the past decade, recommendations to supplement dietary magnesium intake to patients with chronic kidney disease have appeared in the literature,” Galán and colleagues concluded. “Our study suggests that these recommendations should be applied cautiously, if at all.”
Collapse
Read more about
Click Here to Manage Email Alerts